Bristol-Myers, Pfizer to offer Eliquis at discount: WSJ

Bristol-Myers, Pfizer to offer Eliquis at discount: WSJ

In a strategic move to enhance accessibility and affordability, Bristol-Myers Squibb (BMS) and Pfizer have announced a discount program for Eliquis, an oral anticoagulant used to prevent stroke and blood clots in patients with atrial fibrillation and other conditions. The discount program is aimed at reducing the financial burden on patients and increasing the uptake of the medication [1].

The discount program will offer significant savings, including a free 30-day trial, up to 80% off retail prices, and copay assistance programs. These savings are designed to be accessible to patients across various insurance statuses and income levels, making Eliquis more affordable for a broader range of individuals [1].

Eliquis, which gained FDA approval on December 23, 2019, is a Factor Xa inhibitor used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to prevent blood clots in the veins of the legs (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE) in people who have just had hip or knee replacement surgery, to treat DVTs or PEs, and to reduce the risk of them happening again [1].

The discount program is a significant development in the pharmaceutical industry, highlighting the importance of affordability and accessibility in healthcare. By offering Eliquis at a discounted rate, BMS and Pfizer are not only increasing patient compliance but also contributing to better health outcomes for individuals with these conditions [1].

References:
[1] https://www.drugs.com/eliquis.html